GlassScriptPhysician profile
Ziad H Rifai
NPI 1952326845
$5,081.74
in general payments reported to CMS, 2019-2025
42 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $735 · 2021: $611 · 2022: $839 · 2023: $720 · 2024: $790 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.22 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Pfizer INC. | $765.57 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $360.49 | 2019-2025 | Qelbree |
| Amneal Pharmaceuticals LLC | $345.39 | 2021-2025 | Rytary, Crexont |
| Sunovion Pharmaceuticals INC. | $304.91 | 2019-2020 | |
| Lilly USA, LLC | $283.07 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $275.42 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $249.30 | 2022 | |
| Neurocrine Biosciences, INC. | $196.85 | 2023-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $172.91 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $164.87 | 2025 | |
| Genzyme Corporation | $126.01 | 2019-2024 | |
| Biogen, INC. | $116.40 | 2019-2024 | Vumerity, Tysabri |
| Kyowa Kirin, INC. | $90.56 | 2020-2023 | Nourianz |
| Emd Serono, INC. | $86.33 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Rifai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.